@article {7669,
	title = {A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide},
	journal = {Blood},
	volume = {119},
	year = {2012},
	note = {Cited By :75Export Date: 21 February 2017},
	month = {2012},
	pages = {2764 - 2767},
	abstract = {In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM; N = 3846), the overall incidence rate (IR, events per 100 patientyears) of second primary malignancies (SPMs) was 3.62. IR of invasive (hematologic and solid tumor) SPMs was 2.08, consistent with the background incidence of developing cancer. In a separate analysis of pooled data from pivotal phase 3 trials of relapsed or refractory MM (N = 703), the overall IR of SPMs was 3.98 (95\% confidence interval [CI], 2.51- 6.31) with lenalidomide/dexamethasone and 1.38 (95\% CI, 0.44-4.27) with placebo/ dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95\% CI, 1.33-4.33) and 0.91 (95\% CI, 0.23-3.66), respectively; IRs of invasive SPMs were 1.71 (95\% CI, 0.86-3.43) and 0.91 (95\% CI, 0.23-3.66), respectively. The risk of SPMs must be taken into account before initiating lenalidomide treatment. In the context of the observed survival benefit in relapsed or refractory MM patients, the benefit/risk profile of lenalidomide/dexamethasone remains positive. {\textcopyright} 2012 by The American Society of Hematology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858858229\&doi=10.1182\%2fblood-2011-08-373514\&partnerID=40\&md5=3546e59ec36722ab2700b1aedecb7228},
	author = {Dimopoulos, M.A. and Richardson, P.G. and Brandenburg, N. and Yu, Z. and Weber, D.M. and Niesvizky, R. and Morgan, G.J.}
}
